Patents Assigned to NEXTGEN BIOSCIENCE CO., LTD.
  • PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALOPECIA AREATA ACTING AS A FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4
    Publication number: 20240148698
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for SIP receptor's subtypes S1PR1 and S1PR4, and more particularly, relates to a pharmaceutical composition containing as an active ingredient a sphingolipid compound acting as a functional antagonist for S1PR1 and S1PR4, does not cause cardiovascular side effects, and is effective in preventing or treating alopecia areata.
    Type: Application
    Filed: September 26, 2023
    Publication date: May 9, 2024
    Applicant: NEXTGEN BIOSCIENCE CO., LTD.
    Inventors: Bong Yong LEE, Yang Hae PARK, Eun Jeong KIM
  • Pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for S1PR1 and S1PR4
    Patent number: 11957665
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for S1P receptor's subtypes S1PR1 and S1PR4, and more particularly, relates to a pharmaceutical composition containing as an active ingredient a sphingolipid compound acting as a functional antagonist for S1PR1 and S1PR4, does not cause cardiovascular side effects, and is effective in preventing or treating alopecia areata.
    Type: Grant
    Filed: September 26, 2023
    Date of Patent: April 16, 2024
    Assignee: NEXTGEN BIOSCIENCE CO., LTD.
    Inventors: Bong Yong Lee, Yang Hae Park, Eun Jeong Kim
  • PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE ACTING AS A FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4
    Publication number: 20240041836
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for S1PR1 and S1PR4 of S1P receptors, and more specifically, to a pharmaceutical composition including, as an active ingredient, a sphingolipid compound which does not cause cardiovascular side effects by acting as a functional antagonist for S1PR1 and S1PR4 and has an effect of preventing or treating inflammatory bowel disease.
    Type: Application
    Filed: September 28, 2023
    Publication date: February 8, 2024
    Applicant: NEXTGEN BIOSCIENCE CO., LTD.
    Inventors: Bong Yong LEE, Yang Hae PARK, Eun Jeong KIM